Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Top Cited Papers
- 4 June 2009
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 360 (23), 2416-2425
- https://doi.org/10.1056/nejmoa0810787
Abstract
The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti–interleukin-1β monoclonal antibody.Keywords
This publication has 14 references indexed in Scilit:
- Efficacy and safety of rilonacept (interleukin‐1 trap) in patients with cryopyrin‐associated periodic syndromes: Results from two sequential placebo‐controlled studiesArthritis & Rheumatism, 2008
- The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritisArthritis Research & Therapy, 2008
- Anakinra improves sensory deafness in a Japanese patient with Muckle‐Wells syndrome, possibly by inhibiting the cryopyrin inflammasomeArthritis & Rheumatism, 2008
- Use of Anakinra (Kineret) in the Treatment of Familial Cold Autoinflammatory Syndrome with a 16-Month Follow-UpJournal of Cutaneous Medicine and Surgery, 2008
- Primer: inflammasomes and interleukin 1β in inflammatory disordersNature Clinical Practice Rheumatology, 2008
- New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromesRheumatology, 2007
- Natural History and Outcome in Systemic AA AmyloidosisNew England Journal of Medicine, 2007
- Phenotype, Genotype, and Sustained Response to Anakinra in 22 Patients With Autoinflammatory Disease Associated With CIAS-1/NALP3 MutationsArchives of Dermatology, 2006
- The many worlds of reducing interleukin‐1Arthritis & Rheumatism, 2005
- Spectrum of clinical features in Muckle‐Wells syndrome and response to anakinraArthritis & Rheumatism, 2004